Prestige BioPharma Limited
KSE:950210.KS
13500 (KRW) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 643.028 | 119.894 | 67.323 | 161.056 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 572.292 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 4,478.792 | 3,841.792 | 3,414.928 | 3,415.647 | 3,263.992 | 3,146.931 | 1,800.186 | 1,181.812 | 955.456 | 964.046 | 782.583 | 530.443 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -3,835.764 | -3,721.899 | -3,347.605 | -3,254.591 | -3,263.992 | -3,146.931 | -1,800.186 | -1,181.812 | -955.456 | -964.046 | -782.583 | -530.443 | 572.292 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| -5.965 | -31.043 | -49.725 | -20.208 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7,762.919 | 11,906.233 | 8,137.26 | 11,159.023 | 13,292 | 11,070.163 | 5,203.462 | 333.76 | 9,401.192 | 5,388.611 | 2,456.73 | 0 | 5,373.108 | 0 | 0 | 0 | 886.794 |
| General & Administrative Expenses
| 17,381.631 | 19,060.444 | 17,242.858 | -19,966.799 | 19,726.562 | 17,030.181 | 12,358.679 | -3,008.255 | 12,968.009 | 8,797.978 | 5,307.721 | 300.533 | 203.039 | 2,900.622 | 2,490.828 | 336.254 | 84.028 |
| Selling & Marketing Expenses
| -12,121.808 | -15,665.156 | 0 | 0 | 0 | 0 | 0 | 18,587.431 | 0 | 0 | 0 | 7,517.365 | 224.509 | 0 | 0 | 3,808.104 | 286.224 |
| SG&A
| 5,259.823 | 3,395.288 | 17,242.858 | -9,089.753 | 19,726.562 | 17,030.181 | 12,358.679 | 15,579.176 | 12,968.009 | 8,797.978 | 5,307.721 | 7,817.898 | 427.548 | 2,900.622 | 2,490.828 | 4,144.358 | 370.252 |
| Other Expenses
| 316.966 | 0 | 903.125 | 18,682.84 | -1,212.317 | -14,052.544 | 70,516.66 | 15,670.177 | -72,559.935 | -4,829.709 | -3,940.514 | -11,661.053 | 7,174.194 | 3,091.369 | 1,473.031 | -1,780.157 | 19.588 |
| Operating Expenses
| 13,022.742 | 15,301.521 | 17,242.858 | -49,592.377 | 19,726.562 | 17,030.181 | 12,358.679 | 31,249.353 | 12,968.009 | 8,797.978 | 5,307.721 | 3,972.213 | 9,152.328 | 2,900.622 | 2,490.828 | 3,017.208 | 2,493.174 |
| Operating Income
| -16,858.506 | -19,023.42 | -17,175.536 | -20,885.712 | -19,726.562 | -17,030.181 | -12,358.679 | -31,249.354 | -12,968.009 | -8,797.978 | -5,307.721 | -3,972.215 | -9,152.329 | -2,900.622 | -2,490.828 | -3,017.208 | -2,493.175 |
| Operating Income Ratio
| -26.217 | -158.669 | -255.121 | -129.68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.992 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3,616.042 | 7,380.295 | 283.087 | 5,681.442 | -1,382.163 | -2,401.934 | 66,202.454 | -69,922.365 | -72,363.403 | -4,837.796 | -4,862.941 | 6,622.243 | -1,026.633 | 3,030.145 | 2,090.156 | -4,013.226 | -155.57 |
| Income Before Tax
| -13,242.464 | -11,643.125 | -16,892.449 | -15,204.27 | -21,108.725 | -19,432.115 | 53,843.775 | -101,171.719 | -85,331.412 | -13,635.774 | -10,170.662 | 2,646.581 | -10,177.109 | 129.523 | -400.672 | -7,030.434 | -2,648.744 |
| Income Before Tax Ratio
| -20.594 | -97.112 | -250.916 | -94.403 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17.783 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 145.26 | -33.494 | 139.756 | 128.841 | 411.627 | 9.207 | 215.938 | 138.07 | 399.585 | 260.561 | -782.583 | -0.149 | 28.522 | 5.768 | -0.047 | 0.762 | -154.995 |
| Net Income
| -1,447.792 | -13,027.978 | -9,122.322 | -8,806.926 | -14,353.369 | -18,278.442 | 59,277.404 | -101,309.789 | -85,730.997 | -13,896.335 | -10,170.662 | 2,646.73 | -10,205.631 | 123.754 | -400.672 | -7,031.196 | -2,648.744 |
| Net Income Ratio
| -2.252 | -108.663 | -135.501 | -54.682 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17.833 | 0 | 0 | 0 | 0 |
| EPS
| -24.09 | -216.79 | -151.8 | -146.55 | -238.84 | -304.15 | 891 | -8,432.73 | -1,427.2 | -231.8 | -169.24 | 238.16 | -210 | 2.4 | -9.6 | -849.45 | -64 |
| EPS Diluted
| -24.09 | -216.79 | -151.8 | -146.55 | -238.84 | -304.15 | 891 | -8,432.73 | -1,427.2 | -231.8 | -169 | 238.16 | -210 | 2.4 | -9.6 | -849.45 | -57 |
| EBITDA
| -12,379.714 | -15,181.627 | -15,055.959 | 47,542.291 | -19,726.562 | -17,030.181 | -12,358.679 | -183,363.738 | -12,968.009 | -8,797.978 | -5,307.721 | -11,888.766 | -9,800.261 | -2,900.622 | -2,490.828 | -2,465.15 | -2,438.183 |
| EBITDA Ratio
| -19.252 | -126.626 | -223.638 | 295.191 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17.125 | 0 | 0 | 0 | 0 |